Candidate imaging biomarkers for PMP22-related inherited neuropathies.

Published in: Annals of clinical and translational neurology (2022)

MTR, CSA, and circularity showed promise as reliable and sensitive biomarkers of CMT1A, but not HNPP. These warrant longitudinal investigation as response biomarkers in upcoming clinical trials of CMT1A, while other methods should be considered for HNPP.

Keyphrases

clinical trial
high resolution
randomized controlled trial
machine learning
big data
cross sectional
mass spectrometry
fluorescence imaging
deep learning
phase ii
drug induced